Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086651 · ClinicalTrials.gov registry record
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,300
- Enrollment target
NCT07086651 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,300 participants.
The verdict
NCT07086651 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,300 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about how long apalutamide and enzalutamide are taken by men to treat mCSPC. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts of the body. Castration-sensitive prostate cancer means the cancer is being controlled by keeping the testosterone levels as low as would be expected if the testicles were removed by surgery. This is a real-world study, not a clinical study. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). The study will include patients' information from the database for men who: * Were identified to have mCSPC. * Started treatment with apalutamide or enzalutamide (index date) for mCSPC. * Were 18 years of age or older on the index date. Men in this study will be taking apalutamide or enzalutamide for treatment of their mCSPC. The study will compare how long men take apalutamide or enzalutamide. This study will use patient information from cancer clinics. Information from start of apalutamide or enzalutamide treatment until information is available in the database will be used to describe how long patients receive treatment.
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2025-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07086651
The ClinicalTrials.gov registry entry for NCT07086651 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apalutamide is the first listed.
NCT07086651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07086651 about?
NCT07086651 is a clinical study titled "A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)". The purpose of this study is to learn about how long apalutamide and enzalutamide are taken by men to treat mCSPC. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts o...
What is the current status of trial NCT07086651?
This trial is currently completed. The enrollment target is 1,300 participants. The study started on 2025-07-21. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT07086651?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT07086651?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.